

# Martin Hutchings

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9035372/martin-hutchings-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151  
papers

6,800  
citations

35  
h-index

81  
g-index

164  
ext. papers

8,292  
ext. citations

3.7  
avg, IF

5.45  
L-index

#	Paper	IF	Citations
151	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3048-58	2.2	927
150	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3746-52	2.2	667
149	FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. <i>Blood</i> , <b>2006</b> , 107, 52-9	2.2	592
148	FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1514-23	10.3	323
147	Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1188-94	2.2	272
146	Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1160-8	10.3	267
145	Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1786-1794	2.2	264
144	International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 683-90	8.9	224
143	Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma: a systematic review. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1906-14	2.2	214
142	Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4508-14	2.2	191
141	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , <b>2014</b> , 99, 1107-13	6.6	179
140	Position emission tomography with or without computed tomography in the primary staging of Hodgkin lymphoma. <i>Haematologica</i> , <b>2006</b> , 91, 482-9	6.6	175
139	PET/CT for therapy response assessment in lymphoma. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50 Suppl 1, 21S-30S	8.9	158
138	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , <b>2017</b> , 28, 1436-1447	10.3	148
137	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv19-iv29	10.3	142
136	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2014</b> , 25 Suppl 3, iii70-5	10.3	127
135	Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. <i>European Journal of Haematology</i> , <b>2007</b> , 78, 206-12	3.8	90

134	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , <b>2018</b> , 131, 1456-1463	2.2	77
133	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e109-e116	14.6	76
132	Treatment of Hodgkin lymphoma: the past, present, and future. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 543-56		75
131	Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. <i>Hematological Oncology</i> , <b>2006</b> , 24, 146-50	1.3	71
130	In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2705-11	2.2	67
129	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3993-8	2.2	62
128	Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. <i>Haematologica</i> , <b>2012</b> , 97, 931-6	6.6	61
127	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1959-1970	2.2	57
126	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , <b>2020</b> , 135, 735-742	2.2	54
125	Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1352-1358	10.3	52
124	Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 1041-6	7.1	50
123	FDG-PET in the clinical management of Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 52, 19-32	7	46
122	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , <b>2018</b> , 29, 544-562	10.3	42
121	Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 575-80	7.1	40
120	Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 975-80	7.1	40
119	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , <b>2018</b> , 93, 57-68	7.5	37
118	PET/CT in the management of haematological malignancies. <i>European Journal of Haematology</i> , <b>2008</b> , 80, 369-80	3.8	36
117	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , <b>2017</b> , 75, 195-203	7.5	35

116	PET/CT for Staging; Past, Present, and Future. <i>Seminars in Nuclear Medicine</i> , <b>2018</b> , 48, 4-16	5.4	31
115	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 589-595	8.9	31
114	Early interim PET scan in Hodgkin lymphoma: where do we stand?. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 659-62	1.9	31
113	Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. <i>Blood</i> , <b>2020</b> , 136, 45-46	2.2	29
112	The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1095-1099	10.3	28
111	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , <b>2018</b> , 132, 391-391	2.2	25
110	Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 46-48	2.2	25
109	A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 435-44	4.5	24
108	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 236-44	4.5	24
107	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. <i>Lancet, The</i> , <b>2021</b> , 398, 1157-1169	4.0	22
106	Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2349-55	1.9	20
105	(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2005-12	1.9	20
104	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology, the</i> , <b>2021</b> , 8, e410-e421	14.6	20
103	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 322-327	3.1	19
102	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. <i>Blood</i> , <b>2019</b> , 134, 1584-1584	2.2	19
101	Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , <b>2021</b> , 106, 1129-1137	6.6	19
100	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I First in Human Trial. <i>Blood</i> , <b>2018</b> , 132, 226-226	2.2	18
99	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 876-883	4.5	18

98	Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 549-549	2.2	17
97	Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , <b>2019</b> , 104, e151-e153	6.6	17
96	Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 65-75	4.5	16
95	FDG-PET/CT based response-adapted treatment. <i>Cancer Imaging</i> , <b>2012</b> , 12, 324-35	5.6	16
94	First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody <sup>®</sup> -CD3 <sup>®</sup> CD20) in B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , <b>2019</b> , 134, 758-758	2.2	16
93	Epcoritamab (GEN3013; DuoBody-CD3 <sup>®</sup> CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8009-8009	2.2	16
92	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 2871-2871	2.2	15
91	Clinical presentation and staging of Hodgkin lymphoma. <i>Seminars in Hematology</i> , <b>2016</b> , 53, 148-54	4	13
90	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. <i>Blood</i> , <b>2016</b> , 128, 148-148	2.2	12
89	Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma. <i>Radiology: Artificial Intelligence</i> , <b>2020</b> , 2, e200016	8.7	11
88	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , <b>2012</b> , 2012, 322-7	3.1	11
87	Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study. <i>Blood</i> , <b>2018</b> , 132, 2923-2923	2.2	11
86	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , <b>2020</b> , 9, 6565-6575	4.8	11
85	Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group. <i>Acta Oncologica</i> , <b>2017</b> , 56, 608-613	3.2	9
84	ESMO Consensus Conference on malignant lymphoma: management of Ultra-high-risk Patients. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1687-1700	10.3	9
83	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , <b>2021</b> , 5, 2375-2384	7.8	9
82	Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. <i>Cancer Treatment and Research</i> , <b>2015</b> , 165, 125-46	3.5	8
81	FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?. <i>Hematology/Oncology Clinics of North America</i> , <b>2014</b> , 28, 87-103	3.1	8

80	PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. <i>Blood</i> , <b>2017</b> , 130, 736-736	2.2	8
79	B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). <i>Blood</i> , <b>2018</b> , 132, 926-926	2.2	7
78	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. <i>Blood</i> , <b>2019</b> , 134, 2816-2816	2.2	7
77	Comparison of 11 automated PET segmentation methods in lymphoma. <i>Physics in Medicine and Biology</i> , <b>2020</b> , 65, 235019	3.8	7
76	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. <i>Cancer Medicine</i> , <b>2020</b> , 9, 4395-4404	4.8	7
75	Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 671-673	4.5	6
74	Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 233-4	1.9	6
73	Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients?. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1615-6	1.9	6
72	Renal 131I-hippuran extraction in man: effects of dopamine. <i>British Journal of Clinical Pharmacology</i> , <b>2002</b> , 54, 675-7	3.8	6
71	Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. <i>Journal of Nuclear Cardiology</i> , <b>2020</b> , 27, 1698-1707	2.1	6
70	I-MIBG imaging for detection of anthracycline-induced cardiomyopathy. <i>Clinical Physiology and Functional Imaging</i> , <b>2018</b> , 38, 176-185	2.4	5
69	Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1563-9	1.9	5
68	The Complementary Prognostic Role of Baseline and Interim PET in Predicting Treatment Outcome in Advanced-Stage Hodgkin Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 4405-4405	2.2	5
67	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7539-7539	2.3	5
66	Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. <i>Oncologist</i> , <b>2015</b> , 20, 890-5	5.7	4
65	Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. <i>Blood</i> , <b>2018</b> , 132, 2904-2904	2.2	4
64	The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium. <i>Blood</i> , <b>2019</b> , 134, 487-487	2.2	4
63	Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL). <i>Blood</i> , <b>2015</b> , 126, 1978-1978	2.2	4



62	The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2005</b> , 90, 1711-3	6.6	4
61	Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma. <i>PET Clinics</i> , <b>2014</b> , 9, 443-55, vi	2.2	3
60	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1221-3	2.2	3
59	PET imaging in lymphoma. <i>Expert Review of Hematology</i> , <b>2009</b> , 2, 261-76	2.8	3
58	Volume of Abnormal Tumour Tissue on FDG-PET - a Predictor of Progression-Free Survival in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 63, S45	4	3
57	Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. <i>Blood</i> , <b>2020</b> , 136, 15-15	2.2	3
56	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. <i>Blood</i> , <b>2020</b> , 136, 36-36 <sup>2.2</sup>	2.2	3
55	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , <b>2020</b> , 136, 26-28	2.2	3
54	Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS7575-TPS7575	2.2	3
53	Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7518-7518	2.2	3
52	PET-adapted treatment of Hodgkin lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1200-1201	2.2	3
51	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. <i>Hematological Oncology</i> , <b>2021</b> , 39, 185-195	1.3	3
50	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , <b>2021</b> , 5, 4762-4770	7.8	3
49	Cancer mortality does not differ between migrants and Danish-born patients. <i>Danish Medical Journal</i> , <b>2014</b> , 61, A4848	3.8	3
48	New clues to the prognostic challenge of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 277-8	1.9	2
47	Targeted immunotherapy in Hodgkin lymphoma. <i>Blood</i> , <b>2015</b> , 125, 3967-8	2.2	2
46	The role of bone marrow biopsy in Hodgkin lymphoma staging: "to be, or not to be, that is the question"?. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 523-4	1.9	2
45	Routine follow-up scanning of patients with lymphoma: who, when, how, and why?. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 552-3	1.9	2

44	Uptake of FDG in Lemierre syndrome with normal leucocyte scintigraphy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2003</b> , 30, 489	8.8	2
43	Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 16-17	2.2	2
42	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1874-1874	2.2	2
41	Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 8061-8061	2.2	2
40	Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8555-8555 <sup>2.2</sup>	2.2	2
39	Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). <i>Blood</i> , <b>2021</b> , 138, 2478-2478	2.2	2
38	Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , <b>2021</b> , 138, 525-525	2.2	2
37	Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Phase I Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2478-2478	2.2	2
36	Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> ,	1.4	2
35	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , <b>2015</b> , 107-130	0	2
34	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , <b>2021</b> , 5, e510	0.3	2
33	I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. <i>Journal of Nuclear Cardiology</i> , <b>2020</b> , 27, 931-939	2.1	2
32	Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2018</b> , 24, 215-222	2.2	2
31	FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. <i>Clinical and Translational Imaging</i> , <b>2015</b> , 3, 271-281	2	1
30	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. <i>BMC Cancer</i> , <b>2020</b> , 20, 1202	4.8	1
29	Reply to G. Keramida et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4121-2	2.2	1
28	The Role of Imaging in Radiotherapy for Hodgkin Lymphoma <b>2011</b> , 81-89		1
27	When and how to perform surveillance imaging in patients with lymphoma, and is it worth it?. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1015-6	1.9	1



26	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. <i>Blood</i> , <b>2020</b> , 136, 16-18	2.2	1
25	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , <b>2015</b> , 126, 3905-3905	2.2	1
24	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. <i>Blood</i> , <b>2016</b> , 128, 184-184	2.2	1
23	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Blood</i> , <b>2021</b> , 138, 128-128	2.2	1
22	Different Histopathological Subtypes of Hodgkin Lymphoma Have Significantly Different Levels of FDG Uptake.. <i>Blood</i> , <b>2005</b> , 106, 969-969	2.2	1
21	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. <i>Blood</i> , <b>2014</b> , 124, 1630-1630	2.2	1
20	A small change makes a big difference in Hodgkin lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2214-2215	2.2	1
19	Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Cancer Treatment Communications</i> , <b>2015</b> , 4, S1-S11		0
18	Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial. <i>Blood</i> , <b>2021</b> , 138, 2627-2627	2.2	0
17	Axillary lymph nodes on PET in Hodgkin lymphoma after COVID-19 vaccination.. <i>EJHaem</i> , <b>2021</b> , 2, 885-886	2.2	0
16	Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7519-7519	2.2	0
15	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3463-3472	2.2	0
14	Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 697-707	3.8	0
13	Can we improve on ibrutinib in mantle cell lymphoma?. <i>Lancet Haematology</i> , <b>2018</b> , 5, e98-e99	14.6	
12	Reply to H.J adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?". <i>American Journal of Hematology</i> , <b>2016</b> , 91, E2-3	7.1	
11	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , <b>2020</b> , 113-143	0	
10	Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients. <i>Blood</i> , <b>2019</b> , 134, 2841-2841	2.2	
9	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , <b>2019</b> , 134, 4026-4026	2.2	

- 8 Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. *Blood*, **2014**, 124, 2960-2960 2.2
- 7 PET/CT for HL Staging **2016**, 1-13
- 6 Functional Imaging **2011**, 77-95
- 5 Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging. *Blood*, **2011**, 118, 2627-2627 2.2
- 4 Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.. *Blood*, **2012**, 120, 2637-2637 2.2
- 3 Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients. *Blood*, **2012**, 120, 1532-1532 2.2
- 2 The International Prognostic Index Predicts Outcome In Patients With Untreated Nodal Peripheral T-Cell Lymphomas Staged With PET/CT. *Blood*, **2013**, 122, 5077-5077 2.2
- 1 Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. *Cancer Reports*, **2021**, e1524 1.5